GELS vs GRFS vs TLX Stock Comparison

Gelteq, Grifols and Telix Pharmaceuticals Prices as of Oct 26, 2026 Peers: Industry group
GELS Gelteq Ltd
$0.45 -18.2% 1M -63.7% 1Y
Market cap
$4.08M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Manufacturing Healthcare
GRFS Grifols SA
$7.92 +7.8% 1M -16.3% 1Y
Market cap
$5.52B
P/E
11.9x
Revenue (TTM)
—
Div. yield
–
Biotechnology Healthcare
4 wins

Head to Head

4 decided of 12

Grifols leads on 4 of the 12 questions below (Grifols 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGELSGRFSTLXLeader
Larger companyMarket capitalisation $4.08M $5.52B $3.05B GRFS
Cheaper on earningsLower P/E, profitable companies only — 11.9x — –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 8.4x 112.4x GRFS
Faster revenue growthRevenue growth, trailing twelve months — — — –
More profitableNet margin, trailing twelve months — — — –
Better return on capitalReturn on invested capital — — — –
Less leveragedLower net debt / EBITDA — — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -63.7% -16.3% -16.9% GRFS
Better 5-year returnAnnualised price return, 5 years — -9.9%/yr — –
Less volatileAnnualised volatility, 1 year 159.8% 32.4% 55.0% GRFS
Higher overall scoreMean of the five percentile scores vs peers — 57/100 — –

Percentile Scorecard

GELSGRFSTLX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGELSGRFSTLX
Valuation – 99 #6 of 626 –
Growth – – –
Profitability – – –
Financial Health 67 #5 of 13 14 #566 of 658 19 #534 of 658
Shareholder Returns – 56 #161 of 368 –
Overall – 57 –
  • GELS ranked among 13 companies in Pharma Services
  • GRFS ranked among 673 companies in Pharmaceuticals and Biotechnology
  • TLX ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGELSGRFSTLXSPY
1 month -18.2%+7.8%-21.5% -0.8%
3 months -31.8%+2.2%-9.9% +3.5%
6 months -35.3%-2.6%-13.6% +7.0%
Year to date -43.8%-15.3%+20.0% +12.2%
1 year -63.7%-16.3%-16.9% +13.0%
3 years —+1.0%— +86.3%
3 years, per year —+0.3%— +23.1%
5 years —-40.5%— +68.6%
5 years, per year —-9.9%— +11.0%
10 years —-46.6%— +258.0%
10 years, per year —-6.1%— +13.6%

Risk

MeasureGELSGRFSTLXSPY
Volatility, 1Y 159.8%32.4%55.0% 12.7%
Downside volatility, 1Y 122.0%34.1%55.1% 12.7%
Beta vs S&P 500, 1Y 2.060.950.93 1.00
Return / volatility, 1Y -0.40-0.50-0.31 1.02
Max drawdown, 5Y -91.9%-58.9%-69.4% -25.4%
From 52-week high -70.6%-18.5%-28.6% -1.8%
52-week high $1.53$9.72$12.59 $779.14
52-week low $0.39$7.02$6.41 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGELSGRFSTLX
P/E now vs peer median —median 36.5x 11.9xmedian 17.1x —median 17.1x
P/S now vs peer median —median 2.7x 0.6xmedian 8.8x —median 8.8x
EV/EBITDA now vs peer median —median 37.7x —median 17.1x —median 17.1x
P/FCF now vs peer median -6.8xmedian 20.7x 7.6xmedian 18.0x —median 18.0x
P/B now vs peer median 0.5xmedian 2.9x 0.6xmedian 2.1x 6.2xmedian 2.1x
PEG now vs peer median —median 2.04 —median 0.31 —median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGELSGRFSTLX
Cash & equivalents $6.26K $969.15M $251.91M
Total debt $8.91M $44.00B $516.39M
Shares (diluted) 9.27M 681.57M 337.88M
Enterprise value $1.94M $1.86B $2.01B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGELSGRFSTLX
P/E – 11.9x –
P/FCF -6.8x 7.6x –
P/Operating cash flow – – –
P/S – 0.6x –
P/B 0.5x 0.6x 6.2x
P/Tangible book -1.4x 0.9x 6.2x
EV/EBITDA – – –
EV/EBIT – – –
EV/Revenue – – –
EV/FCF – – –
EV/Operating cash flow – – –
PEG (3Y EPS CAGR) – – –

Growth

14 metrics
MetricGELSGRFSTLX
Revenue growth (1Y) – – –
Revenue CAGR (3Y) – – –
Gross profit growth (1Y) – – –
Gross profit CAGR (3Y) – – –
Operating income growth (1Y) – – –
Operating income CAGR (3Y) – – –
Net income growth (1Y) – – –
Net income CAGR (3Y) – – –
EPS growth (1Y) – – –
EPS CAGR (3Y) – – –
Operating cash flow growth (1Y) – – –
Operating cash flow CAGR (3Y) – – –
Free cash flow growth (1Y) – – –
Free cash flow CAGR (3Y) – – –

Profitability

14 metrics
MetricGELSGRFSTLX
Gross margin – – –
EBITDA margin – – –
Operating margin – – –
Pretax margin – – –
Net margin – – –
FCF margin – – –
Operating cash flow margin – – –
Return on equity – – –
Return on assets – – –
Return on invested capital – – –
Return on capital employed – – –
Asset turnover – – –
Cash conversion (OCF / net income) – – –
Stock comp / revenue – – –

Financial Health

11 metrics
MetricGELSGRFSTLX
Debt / assets 0.1% 48.9% 37.9%
Debt / equity 0.0x 1.3x 1.1x
Net debt / EBITDA – – –
Debt / FCF – – –
Liabilities / assets 29.4% 61.4% 64.2%
Equity / assets 70.6% 38.6% 35.8%
Interest coverage – – –
Current ratio 0.1x 2.5x 2.0x
Quick ratio 0.1x 0.8x 1.9x
Cash ratio 0.0x 0.4x 1.2x
Altman Z-score – – –

Shareholder Returns

7 metrics
MetricGELSGRFSTLX
Dividend yield – 1.4% –
Net buyback yield – – –
Shareholder yield – 1.4% 0.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGELSGRFSTLX
Forward P/E – 8.4xFY2026 112.4xFY2026
EPS, next fiscal year – $0.94FY2026 $0.08FY2026
EPS growth, next FY – +10.6%FY2026 –
EPS growth, the year after – +26.6% -37.5%
Revenue, next fiscal year – $8.88BFY2026 $955.04MFY2026
Revenue growth, next FY – +0.0%FY2026 +18.8%FY2026
Revenue growth, the year after – +10.3% +38.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGELSGRFSTLX
Held by institutions – 21.0% 0.9%
Institutions holding – 166 62
Change in shares held, QoQ – -0.5% +23.9%
Institutions buying – 73 47
Institutions selling – 65 7
Buyers to sellers – 1.12 6.71

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GELSGRFSTLX
GELS 1.00 0.11 0.05
GRFS 0.11 1.00 0.13
TLX 0.05 0.13 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GELS, GRFS and TLX?

Grifols (GRFS) is the largest by market capitalisation: Gelteq (GELS) $4.08M, Grifols (GRFS) $5.52B, Telix Pharmaceuticals (TLX) $3.05B.

Which stock has performed better?

Over the past year Grifols (GRFS) returned the most: Gelteq (GELS) -63.7%, Grifols (GRFS) -16.3%, Telix Pharmaceuticals (TLX) -16.9%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Grifols (GRFS) has been the steadiest (Gelteq (GELS) 159.8%, Grifols (GRFS) 32.4%, Telix Pharmaceuticals (TLX) 55.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GELS, GRFS and TLX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Grifols (GRFS) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.